|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||
| Current assets | |||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||
| Prepaid expenses | |||||||||||||||||||
| Trade accounts receivable, net of allowance for credit losses of $2 and $17, respectively | |||||||||||||||||||
| Inventories, current | |||||||||||||||||||
| Deferred transaction costs | |||||||||||||||||||
| Income taxes receivable | |||||||||||||||||||
| Other current assets | |||||||||||||||||||
| Total current assets | |||||||||||||||||||
| Investments held in Trust Account | |||||||||||||||||||
| Property, plant and equipment, net | |||||||||||||||||||
| Deferred transaction costs | |||||||||||||||||||
| Right-of-use assets, net | |||||||||||||||||||
| Inventories, noncurrent | |||||||||||||||||||
| Other noncurrent assets | |||||||||||||||||||
| Total assets | |||||||||||||||||||
| Liabilities and shareholders' deficit | |||||||||||||||||||
| Accrued expenses | |||||||||||||||||||
| Franchise taxes payable | |||||||||||||||||||
| Income tax payable | |||||||||||||||||||
| Excise tax payable | |||||||||||||||||||
| Current liabilities | |||||||||||||||||||
| Accounts payable | |||||||||||||||||||
| Income taxes payable | |||||||||||||||||||
| Accrued expense | |||||||||||||||||||
| Contract liabilities | |||||||||||||||||||
| Line of credit | |||||||||||||||||||
| Legacy SMAP promissory notes | |||||||||||||||||||
| Related party | |||||||||||||||||||
| Legacy SMAP | |||||||||||||||||||
| Total legacy SMAP promissory notes | |||||||||||||||||||
| Right-of-use liabilities, current | |||||||||||||||||||
| Other current liabilities | |||||||||||||||||||
| Total current liabilities | |||||||||||||||||||
| Contract liabilities, noncurrent | |||||||||||||||||||
| Right-of-use-liabilities, noncurrent | |||||||||||||||||||
| Convertible notes, noncurrent | |||||||||||||||||||
| Warrants | |||||||||||||||||||
| Deferred tax liabilities, net | |||||||||||||||||||
| Promissory Notes | |||||||||||||||||||
| Total liabilities | |||||||||||||||||||
| Common stock subject to possible redemption, 1,634,944 and 11,500,000 shares at redemption value of $10.73 and $10.30, respectively, as of September 30, 2023 and December 31, 2022, respectively | |||||||||||||||||||
| Total common stock subject to possible redemption, 1,634,944 and 11,500,000 shares at redemption value of $10.73 and $10.30, respectively, as of September 30, 2023 and December 31, 2022, respectively | |||||||||||||||||||
| Shareholders' equity | |||||||||||||||||||
| Common stock, $0.0001 par value; 300,000,000 shares authorized as of June 30, 2026 and December 31, 2025, and 2,205,648 and 2,007,613 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | |||||||||||||||||||
| Additional paid-in capital | |||||||||||||||||||
| Accumulated deficit | |||||||||||||||||||
| Total shareholders' equity | |||||||||||||||||||
| Total liabilities and shareholders' equity | |||||||||||||||||||
Loading...
